Tectonic offers a high-risk, high-upside biotech setup where a well-funded GPCR platform could unlock first-in-class therapies for major untreated pulmonary hypertension and rare bleeding markets.
Overview
Tectonic Therapeutic is a clinical-stage biotech developing biologic therapies against GPCRs, a historically difficult but highly validated drug-target class. Its GEODe™ platform stabilizes GPCRs to enable selective antibodies and therapeutic proteins. The lead asset, TX45, is a long-acting Fc-relaxin fusion for pulmonary hypertension associated with heart failure, while TX2100 targets HHT, a rare bleeding disorder with no approved therapies. The company is pre-revenue but well capitalized after merger and private financings, with a runway into Q4 2028. Investment appeal is driven by asymmetric clinical upside in large, underserved markets.